SightfileU.S. market data from official filings

RELAY THERAPEUTICS INC (RLAY)

Name: RELAY THERAPEUTICS INC (RLAY) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001812364 · EDGAR filings · Updated 2026-07-21

RELAY THERAPEUTICS INC (RLAY) has reported institutional ownership of 95.9%, with 241 institutional managers holding positions valued at $1.83B per the latest 13F reporting period.

Institutional ownership

95.9%

Institutional managers

241

Reported 13F value

$1.83B

Insider activity

39 trans.

−$2.98M net selling

Latest updates

2026-07-21 — Notice of proposed sale filed (Form 144)
2026-07-20 — Notice of proposed sale filed (Form 144)
2026-07-08 — Insider transaction reported (Form 4)
2026-07-08 — Insider transaction reported (Form 4)
2026-07-08 — Insider transaction reported (Form 4)
2026-07-07 — Notice of proposed sale filed (Form 144)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, RELAY THERAPEUTICS INC has 241 institutional holders and institutional ownership of 95.9%.

Insider activity

Insiders reported 39 transactions (0 buys, 35 sells) across 5 reporting insiders, with a net reported value of −$2.98M.

Related companies

NEKTAR THERAPEUTICS (NKTR) · ADMA BIOLOGICS (ADMA) · SURGERY PARTNERS INC (SGRY) · TAKEDA PHARMACEUTICAL CO LTD (TAK) · GRAIL INC (GRAL) · SIONNA THERAPEUTICS INC (SION)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-21.